TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00326404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel-Ethinyl Estradiol 21 tablets
Description: The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogestrel-Ethinyl Estradiol 28 tablets
Description: The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
Study: NCT05412797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling/Using a DeskCycle
Description: The intervention was conducted in two phases. In phase 1, the intervention group were given the DeskCycles to use for 8 weeks. In phase, the control group from phase 1 were given the DeskCycles to use. Intervention group from phase 1 became controls in phase 2

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular activities
Description: The active comparator performed normal daily activities
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet
Study: NCT03970746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta Injectable Product
Description: For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta Injectable Product
Description: For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
Study: NCT01967238

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IM Pneumococcal, meningococcal, or flu vaccine
Description: Volunteers given one of the 3 vaccines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IM Pneumococcal, meningococcal, or flu vaccine
Description: Volunteers given one of the 3 vaccines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IM Pneumococcal, meningococcal, or flu vaccine
Description: Volunteers given one of the 3 vaccines
Study: NCT04421820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)
Description: 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Description: 320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Description: 320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Description: 320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Description: 320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks
Study: NCT04163341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Common Elements Treatment Approach
Description: The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study: NCT01967849

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose tolerance test

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose tolerance test
Study: NCT04115761

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous dendritic cells
Description: The total 10 doses (1 mL/dose; 2±0.5 × 10\^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous dendritic cells
Description: The total 10 doses (1 mL/dose; 2±0.5 × 10\^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
Study: NCT06595251

Intervention type: OTHER
Intervention: Fit2Play curriculum
Description: Fit2Play is a daily after-school park-based program (Monday-Friday, 2 PM-6 PM) that comprises (1) 60 minutes of physical activity that incorporates multiple sports (soccer, kickball, flag football) and activities from Sports, Play and Active Recreation for Kids (SPARK), a play- and evidenced-based, outcome-oriented, structured, active recreation program for children with a focus on developing and improving motor skills, movement knowledge, social and personal skills; and (2) 20-30 minutes of nutrition education lessons 1-2 times per week that incorporate EmpowerMe4Life, a health and wellness curriculum aligned to the National Health Education Standards for fifth grade and grounded in the American Heart Association's scientific recommendations in promoting heart-healthy lifestyles. Miami-Dade Parks and Recreation is the sponsor of the Fit2Play prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Fit2Play study.
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study: NCT06593015

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological tool for the diagnosis of myosteatosis
Description: Calculation of muscle attenuation at L3 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological tool for the diagnosis of myosteatosis
Description: Calculation of muscle attenuation at L3/L4 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
Study: NCT04215731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab
Description: Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles and mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 2 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restaging
Description: Restaging by pelvic magnetic resonance imaging (MRI)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Chemoradiotherapy
Description: Concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Radical surgery (TME or more extended surgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical surgery (TME or more extended surgery)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging)
Description: Chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherpay with FOLFOX
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
Study: NCT02514083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg PO daily for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
Study: NCT04167657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 24 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy. Sintilimab shall be started no later than 3 weeks after radiation. Radiotherapy can be performed on the same day as sintilimab.
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study: NCT06084026

Intervention type: OTHER
Intervention: ActivPal
Description: Participants will wear the activity meter (a small button like device) on their thigh for a period of 7 days at the following time-points: baseline, 6, 12, 18, 24, 30 and 36 months. The meter will be placed on their thigh at a research visit and mailed back to the study team after 7 days.

Intervention type: OTHER
Intervention: ActivPal
Description: Participants will wear the activity meter (a small button like device) on their thigh for a period of 7 days at the following time-points: baseline, 6, 12, 18, 24, 30 and 36 months. The meter will be placed on their thigh at a research visit and mailed back to the study team after 7 days.
Study: NCT03294707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG10 oral tablet
Description: Active single ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo single dose
Study: NCT03894124

Intervention type: DRUG
Group type: OTHER
Intervention: Doravirine
Description: Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
Study: NCT02231515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Description: Selective laser trabeculoplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pattern laser trabeculoplasty (PLT)
Description: Pattern laser trabeculoplasty (PLT)
Study: NCT04567628

Intervention type: OTHER
Intervention: No Intervention
Description: As this was an observational study, no intervention was administered.

Intervention type: OTHER
Intervention: No Intervention
Description: As this was an observational study, no intervention was administered.
Study: NCT03609645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca block
Description: FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral articular branches block(FAB)
Description: FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)
Study: NCT04174417

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: systolic blood pressure (SBP)
Description: Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mean blood pressure (MBP)
Description: For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory.
Study: NCT03401801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate ganglion block
Description: Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate ganglion block
Description: Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate ganglion block
Description: Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
Study: NCT05684835

Intervention type: PROCEDURE
Intervention: Excision
Description: All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.

Intervention type: PROCEDURE
Intervention: Excision
Description: All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.

Intervention type: PROCEDURE
Intervention: Excision
Description: All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
Study: NCT03562364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AlterG anti-gravity treadmill
Description: The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
Study: NCT03117010

Intervention type: DRUG
Intervention: Steroids
Description: High dose dexamethasone 20 mg PO or IV

Intervention type: DRUG
Intervention: Etoposide
Description: Etoposide 150mg/BSA
Study: NCT01929421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/S-1
Study: NCT02167971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Coil
Description: The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
Study: NCT00364637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Volatile Anesthetic)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia
Study: NCT02266368

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobeal coated stents
Description: Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
Study: NCT02931877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study: NCT03072407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PB-119 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PB-119 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PB-119 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PB-119 injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PB-119 injection placebo
Study: NCT03998306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Probiotics
Description: the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study: NCT02088008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinidipine, valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinidipine, valsartan